RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT ADULT ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ADULT ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Two-Pronged attack on tough blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, veliparib and temozolomide, in adults with acute leukemias that had returned or were hard to treat. The main goal was to find the highest dose patients could safely tolerate. Researchers also wanted to see if the drug comb…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug duo targets Tough-to-Treat leukemia
Disease control CompletedThis study tested whether combining two drugs, sirolimus and azacitidine, could help control high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in adults. The trial enrolled 57 patients whose cancer had returned or who could not tolerate standard high-dose c…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Gentler transplant strategy tested for tough blood cancers
Disease control CompletedThis study tested a two-step, lower-intensity stem cell transplant for patients with high-risk blood cancers like leukemia and lymphoma. The goal was to use milder chemotherapy and radiation before the transplant to reduce side effects while still allowing the donor's immune cell…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC